At an interview about the importance of the EFIC-GRÜNENTHAL Grant and special needs in pain research, with focus on major advances in the treatment of patients suffering from chronic pain. Dott. Alberto Grua, Member of the Corporate Executive Board, CCO EU, Australia and North-America, Grünenthal Group Dr. Matthias Müller, MD, MSc, SVP, Head of Medical Affairs, Grünenthal Europe & Australia and North America
The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 26 percent of revenues in 2012.
Clinical trial disclosure
As of today the Grünenthal Internet Clinical Trial Portal provides public access to information about clinical trials sponsored by Grünenthal.
As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly sharing information about clinical trials. The launch of this portal illustrates Grünenthal’s commitment to enhance research and patient care by providing public access to information (including results) about its interventional clinical trials in patients.